Parkway Clinical Laboratories, INC.

Parkway Clinical Laboratories, INC. was paid $7.56M by Medicaid between Jan 2018 and Nov 2024, across 75 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 22% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Pennsylvania

Rank by total paid#13 of 95

Median peer was paid$153K

This provider vs. median49×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	55,918	$676K
2019	82,362	$931K
2020	127,987	$1.09M
2021	135,229	$2.10M
2022	107,394	$1.88M
2023	36,096	$567K
2024incomplete	19,389	$323K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	22%	29,844	20,059	$1.69M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	18%	88,056	58,538	$1.36M
0223U		11%	4,681	3,423	$863K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	9.7%	19,782	17,116	$733K
80100		7.7%	41,616	16,780	$579K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	6.8%	6,360	3,624	$517K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	6.2%	17,520	11,777	$470K
80101		4.3%	21,839	10,586	$329K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	3.1%	14,024	9,380	$236K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	2.9%	13,723	10,662	$223K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	3,024	2,318	$60K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	5,150	3,940	$31K

63 more codes

80347		<1%	15,009	$27K
80174		<1%	1,504	$24K
80361		<1%	17,549	$23K
80182		<1%	1,504	$23K
80160		<1%	1,504	$21K
80352		<1%	6,645	$19K
80354		<1%	19,612	$19K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	3,769	$18K
80348		<1%	19,066	$17K
80363		<1%	12,060	$17K
80362		<1%	9,729	$16K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	234	$15K
87634		<1%	3,809	$15K
80365		<1%	17,652	$14K
80356		<1%	16,741	$13K
80353		<1%	16,164	$13K
80324		<1%	15,535	$12K
80337		<1%	1,448	$12K
80359		<1%	14,914	$11K
80358		<1%	14,871	$11K
80345		<1%	13,928	$10K
81025		<1%	2,437	$9K
80373		<1%	10,441	$8K
87486		<1%	2,949	$8K
80349		<1%	9,019	$8K
80368		<1%	9,627	$8K
87541		<1%	2,852	$7K
87581		<1%	2,850	$7K
80371		<1%	6,239	$6K
87498		<1%	3,052	$6K
87640		<1%	2,967	$6K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,945	$4K
80346		<1%	1,422	$4K
80321		<1%	2,800	$3K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	242	$3K
83992		<1%	1,749	$3K
80323		<1%	1,859	$3K
80369		<1%	2,461	$3K
84443	Thyroid stimulating hormone (TSH)	<1%	110	$2K
80355		<1%	4,218	$2K
80332		<1%	990	$2K
80061	Lipid panel	<1%	149	$2K
87631		<1%	36	$1K
80053	Comprehensive metabolic panel	<1%	149	$1K
80342		<1%	1,243	$1K
84436		<1%	108	$1K
80372		<1%	183	$961.05
80375		<1%	1,127	$948.40
80360		<1%	409	$901.75
86803		<1%	66	$779.00
80366		<1%	632	$721.41
87340		<1%	25	$366.16
80076		<1%	39	$346.42
80333		<1%	324	$195.23
86592		<1%	66	$160.50
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	26	$152.00
80364		<1%	146	$122.94
0003U	Infec agen detec ampli probe	<1%	266	$93.60
81002		<1%	192	$58.71
86701		<1%	16	$24.00
83036	Hemoglobin; glycosylated (A1C)	<1%	26	$7.00
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	0%	26	$0.00
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	0%	26	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHAIDER, MASOOD (CEO/PRESIDENT)